---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-022236"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:24:53.585568+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q1 2023 revenue down 12% to $376K; gross profit up 61% to $113K

## Summary
- Net loss $2.1M vs $2.2M prior year; cash $5.2M at quarter end.
- Gross margin improved 61% on 17% higher ASP and 15% lower variable cost.
- Revenue decline of 12% due to 27% unit sales drop and termination of less profitable retail channels.
- Innovation pipeline expanded: vagus nerve stimulation program; collaboration with Feinstein Institute.
- Closed $5M financing in Feb 2023; B2B sales portal and price increases implemented in April 2023.

## SEC filing metadata
- accession: 0000950170-23-022236
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/0000950170-23-022236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/tivc-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-022236
- JSON: https://secwatch.observer/filing/0000950170-23-022236.json
- Plain text: https://secwatch.observer/filing/0000950170-23-022236.txt

## Key facts
- Earnings Releases
  Valion Bio, Inc. reported the first quarter 2023 ended March 31, 2023 results: revenue $376 thousand, net income Net loss of $2.1 million.
  - Period: the first quarter 2023 ended March 31, 2023
  - Revenue: $376 thousand
  - Net income: Net loss of $2.1 million
  - Result: reported results
  source text: First Quarter 2023 Financial Summary • Gross profit increased 61.3% to $113 thousand in the first quarter 2023, compared with $70 thousand in first quarter 2022, on a decrease of 12% in total revenue to $376 thousand in the first quarter 2023 from $428 thousand in first quarter 2022. • Net loss of $2.1 million in the first quarter 2023, compared with $2.2 million in first quarter 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/0000950170-23-022236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.